Global Health Technologies Coalition Global Health Technologies Coalition
  • Why R&D
  • R&D Facts
  • In Your State
  • Solutions
  • Breakthroughs Blog
  • News & Events
  • Resources
  • About Us
Stay Informed

Global health R&D delivers forMissouri

Map
Missouri
Select a new state
Select a State
Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois
Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana
Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island
South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming

US government investment in global health R&D has delivered

$73.6 million
to Missouri research institutions
850+ new jobs
for Missouri
Missouri

Neglected diseases in Missouri

Chikungunya cases
Chikungunya cases
24
Dengue cases
Dengue cases
35
HIV diagnoses
HIV diagnoses
4599
Malaria cases
Malaria cases
118
Tuberculosis cases
Tuberculosis cases
855
West Nile cases
West Nile cases
135
Zika cases
Zika cases
38
Missouri's top USG-funded global health R&D institutions

Missouri's top USG-funded global health R&D institutions

Washington University
$60.8 million
Saint Louis University
$7.4 million
University of Missouri-Kansas City
$3.6 million
University of Missouri-Columbia
$1.8 million
University of Missouri-St. Louis
$81 thousand
Missouri industry in global health R&D

Missouri industry in global health R&D

Bayer
Location(s): Kansas City
Charles River Laboratories
Location(s): O’Fallon
Mediomics
Location(s): St. Louis
Pfizer
Location(s): St. Louis
Sanofi
Location(s): St. Louis

Missouri's top areas of global health R&D by USG funding

19%
Malaria
13.5%
Tuberculosis
2.7%
Diarrheal diseases
6.2%
Salmonella infections
44.6%
Neglected tropical diseases
Dengue
Helminths
Kinetoplastids
11%
Other
Bacterial pneumonia & meningitis
Cryptococcal meningitis
Ebola/viral hemorrhagic fevers
Non-allocable
Global health R&D at work in Missouri
Global health R&D at work in Missouri

Researchers from Washington University School of Medicine have discovered that the Zika virus uses the process of autophagy, or cellular waste disposal—a key feature of the placental barrier—to infect the fetus. Their research also showed that an existing malaria drug, hydroxychloroquine, can protect the fetus by blocking this process. The drug is already approved for short-term use in pregnant women. Further studies are needed before it can be used for the duration of pregnancy. Counterintuitively, hydroxychloroquine blocks Zika by lowering the body’s ability to clear out invaders.

Download PDF
Map
Select a new state
Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: Pan American Health Organization
Close
advancing innovation to save lives

© 2009–2021, PATH, as secretariat of the Global Health Technologies Coalition.

Site managed by A3CS

  • Stay Informed
  • Join Us
  • Contact Us
  • GHTC Member Log In